Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 10/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 13/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13441816 | 0.79 | MAPT (0.57) | TP53SMN1; SMN2MAPTRXFP1PPARD | |
| SCHEMBL13407819 | 0.75 | PDPK1 (0.47) | MAPTLMNAPOLBPPARD | |
| SCHEMBL3579790 | 0.74 | MAPT (0.51) | TP53MAPTLMNARXFP1PPARD | |
| SCHEMBL4690917 | 0.72 | CYP1A2 (0.61) | SMN1; SMN2MAPT | |
| SCHEMBL28613817 | 0.71 | MAPT (0.70) | TP53SMN1; SMN2MAPTLMNAPOLB | |
| SCHEMBL12545647 | 0.70 | MAPT (0.49) | TP53SMN1; SMN2MAPTLMNAPOLB | |
| SCHEMBL29217757 | 0.70 | SMN1; SMN2 (0.62) | TP53SMN1; SMN2MAPTLMNAPOLB | |
| SCHEMBL2748380 | 0.70 | MAPT (0.51) | TP53SMN1; SMN2MAPTLMNAPOLB | |
| SCHEMBL30172424 | 0.69 | MAPT (0.48) | TP53SMN1; SMN2MAPTLMNAPOLB | |
| SCHEMBL13224658 | 0.68 | MAPT (0.48) | TP53SMN1; SMN2MAPTLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087468-A1 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087468-A1 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | PPARG, PPARD, PPARA | TP53 3081/4885SMN1; SMN2 4669/4885MAPT 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.